Inhibition of mTORC1 by RAD001 (everolimus) potentiates the effects of 1,25-dihydroxyvitamin D3 to induce growth arrest and differentiation of AML cells in vitro and in vivo

Takashi, 2005, 19-Nor-1,25(OH)2D2 (a novel, noncalcemic vitamin D analogue), combined with arsenic trioxide, has potent antitumor activity against myeloid leukemia, Cancer Res, 65, 2489 Colstone, 1992, Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vitro and in vivo, Biochemical Pharm, 44, 693, 10.1016/0006-2952(92)90405-8 Shabahang, 1993, 1,25-Dihydroxyvitamin D3 receptor as a marker of human colon carcinoma cell line differentiation and growth inhibition, Cancer Res, 53, 3712 Eisman, 1987, Suppression of in vivo growth of human cancer solid tumor xenografts by 1,25-dihydroxyvitamin D3, Cancer Res, 47, 21 Liu, 1996, Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937, Genes Dev, 10, 142, 10.1101/gad.10.2.142 Rots, 1999, Induced differentiation of U937 cells by 1,25-dihydroxyvitamin D3 involves cell cycle arrest in G1 that is preceded by a transient proliferative burst and an increase in cyclin expression, Blood, 93, 2721, 10.1182/blood.V93.8.2721 Elstner, 1999, Novel 20-epi-vitamin D3 analog combined with 9-cis-retinoic acid markedly inhibits colony growth of prostate cancer cells, Prostate, 40, 141, 10.1002/(SICI)1097-0045(19990801)40:3<141::AID-PROS1>3.0.CO;2-C Muto, 1999, 1,25-Dihydroxyvitamin D3 induces differentiation of a retinoic acid-resistant acute promyelocytic leukemia cell line (UF-1) associated with expression of p21(WAF1/CIP1) and p27(KIP1), Blood, 93, 2225, 10.1182/blood.V93.7.2225 Munker, 1996, A new series of vitamin D analogs is highly active for clonal inhibition, differentiation, and induction of WAF1 in myeloid leukemia, Blood, 88, 2201, 10.1182/blood.V88.6.2201.bloodjournal8862201 Wang, 2009, Akt regulates vitamin D3-induced leukemia cell functional differentiation via Raf/MEK/ERK MAPK signaling, Eur J Cell Biol, 88, 103, 10.1016/j.ejcb.2008.05.003 O'Kelly, 2000, Novel Gemini-vitamin D3 analog inhibits tumor cell growth and modulates the Akt/mTOR signaling pathway, J Steroid Biochem Mol Biol, 100, 107, 10.1016/j.jsbmb.2006.04.003 Vivanco, 2002, The phosphatidylinositol 3-kinase-Akt pathway in human cancer, Nat Rev Cancer, 2, 489, 10.1038/nrc839 Inoki, 2002, TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signaling, Nat Cell Biol, 4, 648, 10.1038/ncb839 Bjornsti, 2004, Lost in translation: dysregulation of cap-dependent translation and cancer, Cancer Cell, 5, 519, 10.1016/j.ccr.2004.05.027 Hay, 2004, Upstream and downstream of mTOR, Genes Dev, 18, 1926, 10.1101/gad.1212704 Jacinto, 2004, Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive, Nat Cell Biol, 6, 1122, 10.1038/ncb1183 Sarbassov, 2004, Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton, Curr Biol, 14, 1296, 10.1016/j.cub.2004.06.054 Sarbassov, 2005, Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex, Science, 307, 1098, 10.1126/science.1106148 Nishioka, 2008, Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells, Leukemia, 22, 2159, 10.1038/leu.2008.243 Nishioka, 2009, Inhibition of mammalian target of rapamycin signaling potentiates the effects of all-trans retinoic acid to induce growth arrest and differentiation of human acute myelogenous leukemia cells, Int J Cancer, 125, 1710, 10.1002/ijc.24472 Chan, 2004, Targeting the mammalian target of rapamycin(mTOR): a new approach to treating cancer, Br J Cancer, 91, 1420, 10.1038/sj.bjc.6602162 Haritunians, 2007, Antiproliferative activity of RAD001(everolimus) as a single agent and combined with other agents in mantle cell lymphoma, Leukemia, 21, 333, 10.1038/sj.leu.2404471 Munker, 1996, A new series of vitamin D analogs is highly active for clonal inhibition, differentiation, and induction of WAF1 in myeloid leukemia, Blood, 88, 2201, 10.1182/blood.V88.6.2201.bloodjournal8862201 Ikezoe, 2006, The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling, Mol Cancer Ther, 5, 2522, 10.1158/1535-7163.MCT-06-0071 Ikezoe, 2004, Insulin-like growth factor binding protein-3 antagonizes the effects of retinoids in myeloid leukemia cells, Blood, 104, 237, 10.1182/blood-2003-07-2203 Nishioka, 2008, Inhibition of MEK/ERK signaling synergistically potentiates histone deacetylase inhibitor-induced growth arrest, apoptosis and acetylation of histone H3 on p21(waf1) promoter in acute myelogenous leukemia cell, Leukemia, 22, 1449, 10.1038/sj.leu.2405079 Richon, 2000, Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation, Proc Natl Acad Sci U S A, 97, 10014, 10.1073/pnas.180316197 Nishio, 2004, CCAAT displacement protein/cut homolog recruits G9a histone lysine methyltransferase to repress transcription, Proc Natl Acad Sci U S A, 101, 11257, 10.1073/pnas.0401343101 Nagaki, 2003, Chromatin immunoprecipitation reveals that the 180-bp satellite repeat is the key functional DNA element of Arabidopsis thaliana centromeres, Genetics, 163, 1221, 10.1093/genetics/163.3.1221 Ikezoe, 2005, Oridonin, a diterpenoid purified from Rabdosia rubescens, inhibits the proliferation of cells from lymphoid malignancies in association with blockade of the NF-kappa B signal pathways, Mol Cancer Ther, 4, 578, 10.1158/1535-7163.MCT-04-0277 Archer, 1999, Histone acetylation and cancer, Curr Opin Genet Dev, 9, 171, 10.1016/S0959-437X(99)80026-4 Pepper, 2003, The vitamin D3 analog EB1089 induces apoptosis via a p53-independent mechanism involving p38 MAP kinase activation and suppression of ERK activity in B-cell chronic lymphocytic leukemia cells in vitro, Blood, 101, 24554, 10.1182/blood-2002-07-1984 Hickish, 1993, The effect of 1,25-dihydroxyvitamin D3 on lymphoma cell lines and expression of the vitamin D receptor in lymphoma, Br J Cancer, 68, 668, 10.1038/bjc.1993.406 Koeffler, 2005, Vitamin D2 analog (Paricalcitol; Zemplar) for treatment of myelodysplastic syndrome, Leukemia Res, 29, 1259, 10.1016/j.leukres.2005.04.003 Amir, 2010, A phase 2 trial exploring the effects of high-dose (10,000 IU/day) vitamin D(3) in breast cancer patients with bone metastases, Cancer, 116, 284, 10.1002/cncr.24749 Wietrzyk, 2007, The antitumor effect of lowered doses of cytostatics combined with new analogs of vitamin D in mice, Anticancer Res, 27, 3387 Chiang, 2009, Fish oil enhances the antiproliferative effect of 1alpha, 25-dihydroxyvitamin D3 on liver cancer cells, Anticancer Res, 29, 3591 Park, 2008, Auranofin promotes retinoic acid- or dihydroxyvitamin D3-mediated cell differentiation of promyelocytic leukaemia cells by increasing histone acetylation, Br J Pharmacol, 154, 1196, 10.1038/bjp.2008.197 Marderosian, 2006, Tristetraprolin regulates Cyclin D1 and c-Myc mRNA stability in response to rapamycin in an Akt-dependent manner via p38 MAPK signaling, Oncogene, 25, 6277, 10.1038/sj.onc.1209645 Gregory, 2003, Phosphorylation by glycogen sythase kinase-3 controls c-Myc proteolysis and subnuclear localization, J Biol Chem, 278, 51606, 10.1074/jbc.M310722200 Gera, 2004, AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-Myc expression, J Biol Chem, 279, 2737, 10.1074/jbc.M309999200 Wall, 2008, Translational control of c-MYC by rapamycin promotes terminal myeloid differentiation, Blood, 112, 2305, 10.1182/blood-2007-09-111856 Polek, 2003, p53 is required for 1,25-dihydroxyvitamin D3-inducedG0 arrest but is not required for G1 accumulation or apoptosis of LNCaP prostate cancer cells, Endocrinology, 144, 50, 10.1210/en.2001-210109 Malone, 1993, Inhibition of c- myc in breast and ovarian carcinoma cells by 1, 25-dihydroxyvitamin D3, retinoic acid and dexamethasone, Anticancer Drugs, 4, 201, 10.1097/00001813-199304000-00012 Tong, 1998, Growth regulation of human colon cancer cells by epidermal growth factor and 1, 25-dihydroxyvitamin D3 is mediated by mutual modulation of receptor expression, Eur J Cancer, 34, 2119, 10.1016/S0959-8049(98)00267-6 Yee, 2006, Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies, Clin Cancer Res, 12, 5165, 10.1158/1078-0432.CCR-06-0764 Zent, 2010, The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation, Cancer, 116, 2201